Molecular Signatures Associated with HCV-Induced Hepatocellular Carcinoma and Liver Metastasis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  De Giorgi, Valeria ^b   Buonaguro, Luigi ^a   Worschech, Andrea ^c   Tornesello, Maria Lina ^a   Izzo, Francesco ^a   Marincola, Francesco M ^b   Wang, Ena ^b   Buonaguro, Franco M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS C; HUMAN; HUMAN TISSUE; INTRACELLULAR SIGNALING; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER METASTASIS; PROTEIN PROCESSING;

CARCINOMA, HEPATOCELLULAR; CLUSTER ANALYSIS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPACIVIRUS; HUMANS; LIVER; LIVER NEOPLASMS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION;

EID: 84874119315     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056153     Document Type: Article

References (44)

1. El-Serag HB, Mason AC, (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750.
2. Davila JA, Petersena NJ, Nelson HA, El-Serag HB, (2003) Geographic variation within the United States in the incidence of hepatocellular carcinoma. J Clin Epidemiol 56: 487-493.
3. El-Serag HB, (2002) Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36: S74-83.
4. Romeo R, Colombo M, (2002) The natural history of hepatocellular carcinoma. Toxicology 181-182: 39-42.
5. Schafer DF, Sorrell MF, (1999) Hepatocellular carcinoma. Lancet 353: 1253-1257.
6. Kim JW, Wang XW, (2003) Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? Carcinogenesis 24: 363-369.
7. Block TM, Mehta AS, Fimmel CJ, Jordan R, (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene 22: 5093-5107.
8. Buendia MA, (1998) Hepatitis B viruses and cancerogenesis. Biomed Pharmacother 52: 34-43.
9. Koike K, Moriya K, Kimura S, (2002) Role of hepatitis C virus in the development of hepatocellular carcinoma: transgenic approach to viral hepatocarcinogenesis. J Gastroenterol Hepatol 17: 394-400.
10. Ohata K, Terashima S, (2007) Synthesis and biological activity of enantiomeric pairs of 5-vinylthiolactomycin congeners. Bioorg Med Chem Lett 17: 4070-4074.
11. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR, (2004) Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 35: 1070-1082.
12. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB, (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54: 533-539.
13. Al-Sukhun S, Hussain M, (2003) Current understanding of the biology of advanced bladder cancer. Cancer 97: 2064-2075.
14. Theodorescu D, (2003) Molecular pathogenesis of urothelial bladder cancer. Histol Histopathol 18: 259-274.
15. Groen KA, (1999) Primary and metastatic liver cancer. Semin Oncol Nurs 15: 48-57.
16. Yamane B, Weber S (2009) Liver-directed treatment modalities for primary and secondary hepatic tumors. Surg Clin North Am 89: 97-113, ix.
17. De Giorgi V, Monaco A, Worchech A, Tornesello M, Izzo F, et al. (2009) Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med 7: 85.
18. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM, (2000) High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 18: 457-459.
19. Eisen MB, Spellman PT, Brown PO, Botstein D, (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
20. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227-235.
21. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, et al. (1995) Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 221: 291-298.
22. Buendia MA, (2000) Genetics of hepatocellular carcinoma. Semin Cancer Biol 10: 185-200.
23. Thorgeirsson SS, Grisham JW, (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339-346.
24. Theise ND, Park YN, Kojiro M, (2002) Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 6: 497-512.
25. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, et al. (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113.
26. Blight KJ, Kolykhalov AA, Reed KE, Agapov EV, Rice CM, (1998) Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets. Antivir Ther 3: 71-81.
27. Rosenberg W, (1999) Mechanisms of immune escape in viral hepatitis. Gut 44: 759-764.
28. Falk CS, Mach M, Schendel DJ, Weiss EH, Hilgert I, et al. (2002) NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation. J Immunol 169: 3257-3266.
29. Momburg F, Mullbacher A, Lobigs M, (2001) Modulation of transporter associated with antigen processing (TAP)-mediated peptide import into the endoplasmic reticulum by flavivirus infection. J Virol 75: 5663-5671.
30. Mullbacher A, Lobigs M, (1995) Up-regulation of MHC class I by flavivirus-induced peptide translocation into the endoplasmic reticulum. Immunity 3: 207-214.
31. Herzer K, Falk CS, Encke J, Eichhorst ST, Ulsenheimer A, et al. (2003) Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol 77: 8299-8309.
32. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995-2004.
33. Sakamoto M, Mori T, Masugi Y, Effendi K, Rie I, et al. (2008) Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology 51 (Suppl 1): 42-45.
34. Zender L, Kubicka S, (2008) Molecular pathogenesis and targeted therapy of hepatocellular carcinoma. Onkologie 31: 550-555.
35. Midorikawa Y, Sugiyama Y, Aburatani H, (2010) Molecular targets for liver cancer therapy: From screening of target genes to clinical trials. Hepatol Res 40: 49-60.
36. Okabe H, Furukawa Y, Kato T, Hasegawa S, Yamaoka Y, et al. (2004) Isolation of development and differentiation enhancing factor-like 1 (DDEFL1) as a drug target for hepatocellular carcinomas. Int J Oncol 24: 43-48.
37. Okabe H, Satoh S, Furukawa Y, Kato T, Hasegawa S, et al. (2003) Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res 63: 3043-3048.
38. Yagyu R, Hamamoto R, Furukawa Y, Okabe H, Yamamura T, et al. (2002) Isolation and characterization of a novel human gene, VANGL1, as a therapeutic target for hepatocellular carcinoma. Int J Oncol 20: 1173-1178.
39. Silva FP, Hamamoto R, Nakamura Y, Furukawa Y, (2005) WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferation. Neoplasia 7: 348-355.
40. Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, et al. (2003) Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 103: 455-465.
41. Pang EY, Bai AH, To KF, Sy SM, Wong NL, et al. (2007) Identification of PFTAIRE protein kinase 1, a novel cell division cycle-2 related gene, in the motile phenotype of hepatocellular carcinoma cells. Hepatology 46: 436-445.
42. Sy SM, Lai PB, Pang E, Wong NL, To KF, et al. (2006) Novel identification of zyxin upregulations in the motile phenotype of hepatocellular carcinoma. Mod Pathol 19: 1108-1116.
43. Ip WK, Lai PB, Wong NL, Sy SM, Beheshti B, et al. (2007) Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma. Cancer Lett 250: 284-291.
44. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, et al. (2007) Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67: 6092-6099.